The Inflation Reduction Act: How Price Controls Could Disrupt Clinical Trials and Stifle Medical Innovation
The Inflation Reduction Act of 2022 has introduced drug pricing controls that may initially benefit patients. However, these controls could have unintended consequences on drug development and investment eventually. To mitigate these pressures, there is an opportunity to modernize clinical trials. Dr. Harsha Rajasimha, CEO of Jeeva Informatics, plans to help biopharmaceutical and medical device sponsors reduce the costs of early phase clinical trials and overcome these challenges.